Collaborations & Alliances

Ligand, WuXi Biologics Amend Agreement

Ligand has received $47M as a result of signing an amendment relating to its OmniAb platform agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ligand Pharmaceuticals has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics. This amendment provides WuXi Bio more efficiency in expanding its OmniAb antibody discovery services. Under the previous license agreement, OmniAb antibodies discovered and sub-licensed by WuXi Bio generated potential pre-defined contract payments to Ligand and potential royalties on global product sales. Under the amended agreement, Ligand will co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters